A platelet marker and detection kit for detecting breast cancer

By analyzing the expression levels of ZNF185, DNAJC8 and VCL in platelets, a breast cancer diagnosis model was constructed, which solved the problems of low sensitivity and insufficient specificity of existing breast cancer markers, and achieved early detection of high sensitivity and specificity, overcoming The dilemma of early diagnosis of breast cancer.

CN118853892BActive Publication Date: 2024-12-06WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411366943.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-12-06
Estimated Expiration
2044-09-29

AI Technical Summary

Technical Problem

Existing breast cancer markers are low in sensitivity, especially inadequate specificity in early detection, and single markers are difficult to reflect the overall characteristics of the tumor, with ultrasound and mammography having limitations in remote areas and high costs.

Method used

Platelets were used as liquid biopsy material to analyze the expression levels of ZNF185, DNAJC8 and VCL in platelets, and a diagnostic model was constructed to improve the sensitivity and specificity of early detection of breast cancer.

Benefits of technology

The distinction between breast cancer patients and non-cancer individuals was achieved, and the accuracy of the diagnostic model in the independent verification set reached more than 95%, overcoming the limitations of existing markers and providing a new early diagnosis strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118853892B_ABST
    Figure CN118853892B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of breast cancer detection, and specifically relates to a platelet marker and a detection kit for detecting breast cancer. The present invention first performs transcriptome sequencing on platelets of healthy individuals and breast cancer patients, and then identifies genes that are specifically differentially expressed in platelets of breast cancer patients for the first time through differential expression analysis, and screens out ZNF185, DNAJC8 and VCL genes. A logistic regression model was constructed based on the mRNA expression levels of the three genes. In the receiver operating characteristic curve analysis of the training set, the area under the curve was as high as 0.987, and in the validation set, the AUC value was as high as 1. The present invention mainly uses liquid biopsy to clarify the application of the expression levels of platelet genes ZNF185, DNAJC8 and VCL in the diagnosis of breast cancer, which is used to predict the occurrence of breast cancer, aiming to identify a new marker for breast cancer, and prepare a breast cancer diagnosis kit based on this.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of breast cancer detection, and specifically relates to a platelet marker and a detection kit for detecting breast cancer. Background Art

[0002] Breast Cancer (BC) ranks first in the incidence and mortality of female malignant tumors worldwide. The incidence and mortality of breast cancer in my country are also increasing year by year. It is particularly important to screen, diagnose and treat breast cancer early. Improving the early diagnosis rate is a key way to fundamentally improve the prognosis of breast cancer. Existing breast cancer markers, such as CA153, CEA, CA125, etc., have low sensitivity in early detection of breast cancer, especially for patients with localized breast cancer, the expression levels of these markers may not increase significantly. In addition, these markers may also increase in some benign diseases (such as inflammatory diseases), resulting in insufficient specificity. Moreover, breast cancer is a highly heterogeneous disease, and different subtypes of breast cancer have significant differences in genetic and molecular characteristics. A single tumor marker is difficult to reflect the overall characteristics of the tumor or be applicable to all breast cancer patients. Ultrasound and mammography (mammography) are currently important means for clinical screening and early detection of breast cancer. Although these technologies are widely used in breast cancer detection, especially for early detection of tumors, they are not applicable in remote areas or areas with relatively backward medical technology. Furthermore, the costs of ultrasound and mammography are relatively high, especially for frequent screening or early monitoring.

[0003] The inability to effectively detect cancer at an early stage is a major challenge for breast cancer markers. Based on the above problems, it is particularly important to find new, more convenient and efficient breast cancer tumor markers.

[0004] Therefore, based on this, the technical solution of the present invention is proposed. Summary of the invention

[0005] The technical concept of the present invention is: platelets are the second largest cell type in the blood after red blood cells. They not only play a key role in hemostasis, thrombosis and inflammation, but also participate in cancer-related processes such as epithelial-mesenchymal transition, metastasis, angiogenesis and immune escape. Liquid biopsy technology has received more and more attention in recent years and has become an emerging, non-invasive diagnostic and monitoring tool. Among the many biomarkers, platelets have gradually shown their great potential as liquid biopsy materials due to their unique biological characteristics and multiple roles in cancer. First, during tumorigenesis, the morphology and mRNA transcription spectrum of platelets will change, which can be used as a marker for tumor development; secondly, the high abundance and stability of platelets in peripheral blood make them easy to obtain and process, and can provide a reliable source for cancer-related molecular analysis. Compared with other detection materials, such as circulating tumor DNA or exosomes, the sample processing process of platelets is relatively simple, and the stability of platelets in the blood can ensure the integrity of the markers and reduce interference factors in the detection. By analyzing RNA and proteins inside platelets, researchers can capture the molecular characteristics of tumors and even discover mutations or markers that are difficult to detect with traditional tissue biopsies, thereby achieving more accurate cancer management. These characteristics of platelets make them a promising tool in the field of liquid biopsy, helping to promote the development of personalized medicine and provide patients with more accurate and efficient cancer management strategies.

[0006] In order to solve the problems existing in the prior art, the present invention provides a platelet marker for detecting breast cancer, wherein the platelet marker includes ZNF185, DNAJC8 and VCL.

[0007] Based on the same technical concept, another embodiment of the present invention is to provide a use of a platelet marker in preparing a kit for detecting breast cancer, wherein the platelet marker includes ZNF185, DNAJC8 and VCL.

[0008] Based on the same technical concept, another embodiment of the present invention is to provide a detection kit for breast cancer, wherein the detection kit comprises a detection reagent for detecting platelet markers, and the platelet markers include ZNF185, DNAJC8 and VCL.

[0009] Preferably, the detection reagent is a primer, and the primer is used to detect the expression level of ZNF185, DNAJC8 and VCL.

[0010] Preferably, the detection kit also includes the sample cDNA to be tested, DNA polymerase, four deoxynucleotide triphosphates, SYBR Green I, Mg 2+, buffer, enzyme-free water, EDTA reagent, Trizol reagent and primers of internal reference genes GAPDH and β-actin.

[0011] Preferably, the sample to be tested is a human blood sample.

[0012] In the present invention, ZNF185, DNAJC8 and VCL gene combination are used as new targets for breast cancer diagnosis by the following method:

[0013] (1) Collect, separate and extract platelet samples from patients;

[0014] (2) Extraction and quality control of platelet RNA;

[0015] (3) Construction of RNA-seq library of platelet samples and sequencing analysis of ZNF185, DNAJC8 and VCL gene expression;

[0016] (3) Determination of ZNF185, DNAJC8, and VCL gene expression in additional healthy subjects and breast cancer patients;

[0017] (5) The RT-qPCR method was validated in healthy subjects and breast cancer patients.

[0018] The beneficial effects of the present invention are:

[0019] By analyzing the platelet transcriptomes of healthy individuals and breast cancer patients, it was found that ZNF185, DNAJC8 and VCL genes were significantly different in cancer patients, and the diagnostic model constructed by the above three genes showed excellent performance. This model not only showed high sensitivity and specificity in distinguishing breast cancer patients from non-cancer individuals, but also achieved an accuracy of more than 95% in the independent validation set, showing its great potential in clinical applications. The present invention mainly detects the expression of platelet ZNF185, DNAJC8 and VCL genes in the patient's peripheral blood to determine the occurrence of breast cancer, so as to achieve the purpose of early screening. Moreover, the molecular mechanisms of these genes in the study of breast cancer mechanisms have not been fully revealed, and have not yet been applied in the development of diagnostic reagents. The combination of these genes is expected to provide a new strategy for the diagnosis of breast cancer.

[0020] That is, the present invention has constructed a breast cancer diagnosis application based on a group of genes including platelet ZNF185, DNAJC8 and VCL through large-sample clinical research, which overcomes many limitations of current breast cancer markers, opens up a new model for early diagnosis and exploration of breast cancer, and provides the possibility to fundamentally improve the dilemma of early diagnosis of breast cancer and the prognosis of breast cancer patients, which is conducive to clinical promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 This is a result graph of genes that are significantly differentially expressed in platelets of healthy individuals and breast cancer patients, screened out through differential expression analysis.

[0023] Figure 2 This is the result of univariate logistic regression analysis of the three genes with the largest odds ratio among the differentially expressed genes.

[0024] Figure 3 This is the expression difference result of ZNF185 in platelets of non-cancer individuals (n=55) and breast cancer patients (n=15) obtained by transcriptome sequencing (Wilcoxon rank sum test was used for statistics, ****P<0.0001).

[0025] Figure 4 This is the expression difference result of DNAJC8 in platelets of non-cancer individuals (n=55) and breast cancer patients (n=15) obtained by transcriptome sequencing (Wilcoxon rank sum test was used for statistics, ****P<0.0001).

[0026] Figure 5 This is the expression difference result of VCL in platelets of non-cancer individuals (n=55) and breast cancer patients (n=15) obtained by transcriptome sequencing (Wilcoxon rank sum test was used for statistics, ****P<0.0001).

[0027] Figure 6 The expression level of ZNF185 in platelets of healthy individuals (n=15) and breast cancer patients (n=15) obtained by RT-qPCR (Wilcoxon rank sum test was used for statistics; ****P<0.0001).

[0028] Figure 7 The expression level of DNAJC8 in platelets of healthy individuals (n=15) and breast cancer patients (n=15) obtained by RT-qPCR (Wilcoxon rank sum test was used for statistics; ****P<0.0001).

[0029] Figure 8The expression level of VCL in platelets of healthy individuals (n=15) and breast cancer patients (n=15) obtained by RT-qPCR (Wilcoxon rank sum test was used for statistics; ****P<0.0001)

[0030] Fig. 9 The ROC curve of the univariate logistic regression model constructed based on the expression level of ZNF185 in the training set and the validation set (the X-axis represents the true negative rate, that is, specificity %; the Y-axis represents the true positive rate, that is, sensitivity %).

[0031] Fig.10 Figure 3 is the ROC curve of the univariate logistic regression model constructed based on DNAJC8 expression level in the training set and validation set (the X-axis represents the true negative rate, i.e., specificity %; the Y-axis represents the true positive rate, i.e., sensitivity %).

[0032] Fig.11 Figure 3 is the ROC curve of the univariate logistic regression model constructed based on VCL expression level in the training set and validation set (the X-axis represents the true negative rate, i.e., specificity %; the Y-axis represents the true positive rate, i.e., sensitivity %).

[0033] Fig.12 The figure shows the ROC curves of the multivariate logistic regression model constructed by integrating the expression levels of the three genes ZNF185, DNAJC8 and VCL in the training set and the validation set (the X-axis represents the true negative rate, i.e., specificity %; the Y-axis represents the true positive rate, i.e., sensitivity %). DETAILED DESCRIPTION

[0034] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.

[0035] Example

[0036] Note: Unless otherwise specified, the materials and reagents used in this example can be obtained from commercial sources.

[0037] In addition, in order to screen new highly specific markers that can diagnose breast cancer, the present invention studied the peripheral whole blood of 70 patients (55 healthy people and 15 breast cancer patients) collected from West China Hospital of Sichuan University. The collected whole blood was stored in 10 ml EDTA-coated BD vacuum blood collection tubes containing the anticoagulant EDTA. EDTA inhibits the immediate activation and aggregation of platelets through calcium chelation, thereby blocking the coagulation cascade reaction. In order to minimize the degradation of platelet RNA, whole blood stored in vacuum tubes needs to be separated within 6 hours at room temperature or 4°C.

[0038] 1. Collection and storage of platelets

[0039] The venous blood of the subjects was collected in a 10 mL anticoagulant tube and centrifuged to separate platelets within 2 hours at room temperature. First, centrifuge at 120g for 20 minutes at room temperature to separate into two layers. The upper platelet-rich plasma was transferred to a new EP tube (note that part of the plasma should be retained when aspirating, not all of it), and then centrifuged at 360g for 20 minutes. The precipitate is the platelet, which was washed twice with PBS and RNA was extracted after adding 300 μL of DEPC water.

[0040] (II) Platelet RNA extraction (blood total RNA rapid extraction kit, BioTeKe)

[0041] (1) Add 900 μL of lysis buffer to the platelet suspension and pipette to lyse.

[0042] (2) Centrifuge at 12,000 rpm for 10 min at 4°C and transfer the supernatant to a new enzyme-free EP tube;

[0043] (3) Add 180 μL of chloroform, vortex for 15 seconds, and incubate at room temperature for 10 minutes;

[0044] (4) Centrifuge at 12000 rpm for 10 min at 4°C and collect the upper aqueous phase;

[0045] (5) Add an equal volume of 70% ethanol, invert to mix, and transfer to adsorption column RA;

[0046] (6) Centrifuge at 1000 rpm for 3 min and discard the waste liquid;

[0047] (7) Add 500 μL of deproteinized solution RE, centrifuge at 12000 rpm for 3 min, and discard the waste liquid;

[0048] (8) Add 700 μL of RE rinse solution, centrifuge at 12000 rpm for 3 min, and discard the waste liquid;

[0049] (9) Add 500 μL of RE rinse solution for a second rinse, centrifuge at 12000 rpm for 3 min, and discard the waste liquid;

[0050] (10) Centrifuge at 12000 rpm for 5 min and discard the remaining liquid;

[0051] (11) Place the adsorption column RA into a new enzyme-free EP tube, add 30 μL of RNase free water that has been in a 56°C water bath, and centrifuge at 12,000 rpm for 3 min to collect platelet RNA;

[0052] (12) RNA quality control testing was performed using Agilent 2100. Only samples with a RIN > 7 and a total amount ≥ 10 pg were defined as qualified quality control specimens and could be used for subsequent sequencing.

[0053] 3. Platelet sample RNA-seq library construction and sequencing

[0054] Sequencing strategy: Hiseqxten, PE151 sequencing; Library construction process: Transcriptome library construction, firstly, the qualified samples were digested with DNase I, then the mRNA was separated with oligo (dT) magnetic beads, the mRNA was broken into certain fragments by ultrasound, cDNA was synthesized, and then the DNA fragment ends were repaired, "A" was added to the 3' end of the fragment, and then the library adapter was connected, PCR was performed, and the hybridization library was constructed.

[0055] 4. Platelet RNA-seq raw data processing

[0056] First, the raw data images obtained by sequencing were converted into standard Fastq format sequence information with double-end 150 base pairs using Illumina's bcl2fastq software. Then, the raw RNA sequencing reads data were strictly quality controlled using TrimGalore (v0.6.7) software, including the removal of low-quality data and trimming and shearing of adapter sequences to improve data quality. Subsequently, the clean reads were accurately aligned to the human reference genome (GRCh38) using HISAT2 (v2.2.1). Finally, featureCounts (v2.0.0) software was used in combination with the NCBI gene annotation gtf file GRCh38.84 version to calculate the number of reads mapped on genomic features (such as genes, exons, promoters, etc.).

[0057] 5. Data Analysis

[0058] The present invention uses edgeR (v3.40.2) to perform statistical tests between healthy human platelets and breast cancer platelets. The present invention sets the threshold of logFC (log-fold change) to 1 to ensure the significance of gene expression changes; at the same time, the threshold of logCPM (log-counts per million) is set to 3 to exclude the interference of low-expression genes. In addition, the present invention uses FDR (false discovery rate) correction and sets the threshold to 0.05 to control the false positive rate caused by multiple comparisons. The present invention also excludes genes located on the Y chromosome and limits the analysis objects to protein-coding genes to ensure the biological significance and clinical relevance of the research results. After this series of screening conditions, we finally identified a series of genes that were significantly upregulated or downregulated in breast cancer platelets (such as Figure 1 This study provides a new perspective for the diagnosis of breast cancer.

[0059] In order to evaluate the relationship between the mRNA expression level of a single gene and the binary dependent variable (breast cancer vs. non-cancer), this example performed a univariate logistic regression analysis on the genes that were significantly upregulated or downregulated in breast cancer. Among these genes, ZNF185, DNAJC8, and VCL genes showed significantly better odds ratios than other genes (e.g. Figure 2 As shown in Figure 3), this indicates that the expression levels of ZNF185, DNAJC8 and VCL genes in breast cancer are significantly increased compared with those in the non-cancerous state, and their expression changes have a strong predictive ability for the occurrence of breast cancer.

[0060] In this example, the above platelet transcriptome data were used to normalize the gene expression values ​​with platelets from non-cancer patients as controls to calculate the expression levels of ZNF185, DNAJC8, and VCL in non-cancer individuals and breast cancer patients (the results are shown in Figure 3~Figure 5 ZNF185 and VCL were significantly upregulated in the platelets of patients, while DNAJC8 was significantly downregulated in the platelets of patients.

[0061] 6. Verification of ZNF185, DNAJC8 and VCL expression levels in platelets from clinical samples

[0062] In the present invention, according to the above-mentioned platelet separation method, additional platelet samples were collected from 15 non-cancer individuals and 15 breast cancer patients. Furthermore, in this example, the expression levels of ZNF185, DNAJC8 and VCL in these samples were detected using RT-qPCR technology. Table 1 below shows the primers used.

[0063] Table 1

[0064]

[0065] The results are as follows Figure 6~Figure 8 As shown, compared with non-cancer individuals, the mRNA expression levels of ZNF185 and VCL in platelets of breast cancer patients were significantly increased, while the mRNA expression level of DNAJC8 was significantly decreased.

[0066] (VII) ROC performance test

[0067] The differences in the mRNA expression levels of ZNF185, DNAJC8, and VCL in platelets between healthy individuals and breast cancer patients were evaluated by using the receiver operating characteristic (ROC) curve and its area under the curve (AUC), and the test performance was further evaluated.

[0068] First, the transcriptome data of platelets in 70 patients were used as training sets, and a univariate logistic regression model was constructed based on the expression levels of ZNF185, DNAJC8, and VCL to predict the occurrence of breast cancer. On the training set, these univariate regression models performed well, with AUC values ​​reaching above 0.90 (e.g. Figure 9~Figure 11 ). Subsequently, in this example, the qPCR values ​​of ZNF185, DNAJC8, and VCL in an additional 30 patients were used as validation sets to verify the robustness of each regression model. The validation results were satisfactory, and the AUC of each model on the validation set reached 1 (as shown in Figure 9~Figure 11 Then, the expression levels of these three genes were further integrated to construct a multi-factor logistic regression model for accurate diagnosis of breast cancer. The AUC value of this multi-factor model in the training set was increased to 0.989, and the sensitivity and specificity were as high as 100% and 94.5%, respectively (as shown in Figure 2). Fig.12 As shown in the figure, the AUC value in the validation set remains 1. These results fully confirm the strong ability and stability of platelet genes ZNF185, DNAJC8 and VCL in breast cancer prediction.

[0069] 8. Conclusion

[0070] The present invention found through research that ZNF185 and VCL genes are highly expressed in platelets in breast cancer patients and lowly expressed in normal people; while DNAJC8 gene is lowly expressed in platelets in breast cancer patients and highly expressed in normal people. Based on this, a logistic regression model was constructed according to the expression levels of ZNF185, DNAJC8 and VCL genes, and the AUC value of the model reached 0.987 in the test set. Furthermore, the mRNA expression levels of ZNF185, DNAJC8 and VCL were detected in additional healthy individuals and breast cancer patients using real-time quantitative polymerase chain (RT-qPCR) technology. The results showed that their differences were statistically significant (P<0.05). Then, ROC analysis was performed in the validation set, and the results showed that the AUC value was as high as 1.

[0071] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A platelet marker for detecting breast cancer, It is characterized in that The platelet markers consist of ZNF185, DNAJC8 and VCL.

2. Use of platelet markers in the preparation of a kit for detecting breast cancer, It is characterized in that The platelet markers consist of ZNF185, DNAJC8 and VCL.

3. A detection kit for breast cancer, It is characterized in that The detection kit comprises detection reagents for detecting platelet markers, and the platelet markers consist of ZNF185, DNAJC8 and VCL.

4. The detection kit according to claim 3, It is characterized in that The detection reagent is a primer, and the primer is used to detect the expression levels of ZNF185, DNAJC8 and VCL.

5. The detection kit according to claim 3, It is characterized in that The detection kit also includes a sample cDNA to be tested, DNA polymerase, four deoxynucleotide triphosphates, SYBR Green I, Mg 2+ , buffer, enzyme-free water, EDTA reagent, Trizol reagent and primers of internal reference genes GAPDH and β-actin.

6. The detection kit according to claim 5, It is characterized in that The sample to be tested is a human blood sample.